ZLDPF
Zealand Pharma A/S OTC$45.30
Mkt Cap $3.2B
52w Low $35.93
19.9% of range
52w High $83.12
50d MA $46.93
200d MA $64.08
P/E (TTM)
0.5x
EV/EBITDA
3.9x
P/B
0.2x
Debt/Equity
0.0x
ROE
47.9%
P/FCF
5.0x
RSI (14)
—
ATR (14)
—
Beta
0.57
50d MA
$46.93
200d MA
$64.08
Avg Volume
2.6K
About
Zealand Pharma A/S, a biotechnology company, engages in the discovery, development, and commercialization of peptide-based medicines in Denmark. It has a portfolio of medicines focusing on gastrointestinal and metabolic diseases, and other specialty disease areas with unmet medical needs. The company markets lixisenatide under the brand names of Adlyxin and Lyxumia; Dasiglucagon, a single use syri…
Recent Earnings
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Feb 19, 2026 | AMC | -1.26 | -0.81 | +35.6% | 60.42 | +0.0% | +0.0% | +0.0% | -6.3% | -5.5% | -5.7% | — |
| Nov 13, 2025 | AMC | -1.11 | -0.90 | +18.9% | 80.50 | -2.9% | +0.0% | -1.2% | -1.2% | -2.1% | +3.3% | — |
| Aug 14, 2025 | AMC | 17.22 | 16.06 | -6.7% | 55.02 | +4.3% | +4.5% | +10.9% | +10.9% | +10.9% | +10.9% | — |
| May 8, 2025 | AMC | -0.77 | -0.67 | +13.0% | 63.26 | +1.8% | +1.8% | +0.0% | +0.8% | -1.7% | -4.4% | — |
| Feb 20, 2025 | AMC | -0.74 | -0.59 | +20.8% | 108.30 | +0.0% | +0.0% | -7.7% | -7.7% | -9.0% | -9.7% | — |
| Nov 7, 2024 | AMC | -0.62 | -0.56 | +9.7% | 119.04 | +3.7% | +2.3% | +5.8% | +1.0% | -2.5% | -3.3% | — |
| Aug 15, 2024 | AMC | -0.61 | -0.67 | -9.8% | 136.99 | +3.5% | +3.5% | -1.7% | -3.3% | -2.7% | -3.5% | — |
| May 16, 2024 | AMC | -0.60 | -0.54 | +9.4% | 91.15 | -3.7% | -3.9% | -2.7% | -0.5% | -1.6% | -3.0% | — |
| Feb 27, 2024 | AMC | -0.58 | -0.66 | -13.8% | 90.00 | +3.9% | +4.4% | +7.8% | +6.6% | +7.7% | +12.1% | — |
| Nov 9, 2023 | AMC | -0.53 | 0.18 | +134.0% | 41.91 | -3.6% | -3.6% | -3.6% | -0.6% | -0.6% | -0.6% | — |
Recent Analyst Ratings
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| May 12 | Needham | Maintains | Buy → Buy | — | $11.14 | $11.14 | +0.0% | +0.0% | +0.0% | +0.0% | +0.0% | +0.0% |
| Nov 12 | Morgan Stanley | Maintains | Overweight → Overweight | — | $33.40 | $33.40 | +0.0% | +0.0% | +0.0% | +0.0% | +7.8% | +7.8% |
| Oct 12 | Morgan Stanley | Maintains | Overweight → Overweight | — | $42.30 | $42.30 | +0.0% | +0.0% | +0.0% | -2.1% | -2.1% | -2.1% |
| Aug 13 | Morgan Stanley | Maintains | Overweight → Overweight | — | $35.63 | $35.63 | +0.0% | +0.0% | +0.0% | +0.0% | +0.0% | +0.0% |
| Jul 14 | Morgan Stanley | Maintains | Overweight → Overweight | — | $38.25 | $34.40 | -10.1% | -10.1% | -10.1% | -10.1% | -10.1% | -6.8% |
| Apr 14 | Morgan Stanley | Maintains | Overweight → Overweight | — | $24.60 | $24.60 | +0.0% | +0.0% | +0.0% | +0.0% | +0.0% | +0.0% |
| Mar 30 | Morgan Stanley | Maintains | Overweight → Overweight | — | $24.60 | $24.60 | +0.0% | +0.0% | +0.0% | +0.0% | +0.0% | +0.0% |
| Jan 16 | Morgan Stanley | Maintains | Overweight → Overweight | — | $36.10 | $36.10 | +0.0% | +0.0% | +0.0% | +0.0% | +0.0% | +0.0% |
| Nov 18 | Jefferies | Downgrade | Buy → Hold | — | $33.10 | $33.10 | +0.0% | +0.0% | +0.0% | +0.0% | +0.0% | -5.0% |
| Nov 14 | Morgan Stanley | Maintains | Overweight → Overweight | — | $31.92 | $33.10 | +3.7% | +3.7% | +3.7% | +3.7% | +3.7% | +3.7% |
Data updated apr 27, 2026 8:55pm
· Source: massive.com